REGN vs TYL · P/E 14, rev $14.34B vs P/E 89, rev $2.14B
Regeneron Pharmaceuticals Inc (REGN) versus Tyler Technologies Inc (TYL) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Tyler Technologies Inc (TYL) is a software - application company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported TYL revenue for 2024-12-31 was $2.14B. Net income was $263.0M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. TYL currently screens at market cap $25.57B and trailing P/E 89.3.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. TYL currently screens at market cap $25.57B and trailing P/E 89.3.
Not investment advice. Open the REGN and TYL stock pages for the full models.
Not investment advice.